Responsive Nanomicellar Theranostic Cages for Metastatic Breast Cancer

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Metastasis in triple-negative breast cancer (TNBC) poses a significant clinical challenge due to limited diagnostic specificity.
• Effective therapeutic strategies for TNBC, especially those targeting metastasis, are urgently needed.

Purpose of the Study:

• To develop and characterize a novel amphipathic chitosan-based targeted nanomicellar theranostic system for TNBC.
• To evaluate the diagnostic and therapeutic potential of the nanomicelles, including drug delivery, MRI contrast enhancement, and hyperthermia-induced effects.

Main Methods:

• Synthesis of doxorubicin-superparamagnetic iron oxide nanoparticle complexes within chitosan-based nanomicelles.
• Conjugation of anti-αvβ3 integrin antibody to PEGylated micelles for targeted delivery.
• In vitro evaluation of micellar stability, drug release, cellular uptake, and hyperthermia effects.
• In vivo assessment using a 4T1 orthotopic spontaneous metastasis model in mice, including MRI analysis.

Main Results:

• Developed nanomicelles (30-45 nm) with high doxorubicin-SPION loading (89.23%) and low critical micelle concentration (0.1 μg/mL).
• Demonstrated concentration-dependent MRI contrast enhancement (r2 = 6.27 mM-1 s-1) and hyperthermia capabilities.
• Antibody conjugation significantly enhanced micellar internalization and magnetic labeling of drug-resistant MDA-MB-231 cells.
• Observed retarded cancer cell migration, reduced mitochondrial membrane potential under hyperthermia, and significant antitumor effects with fibrosis-mediated tumor suppression in vivo.
• Achieved simultaneous antitumor efficacy and enhanced MRI-T2 contrast in the metastasis model.

Conclusions:

• The developed targeted nanomicellar theranostics offer a promising dual-modality approach for early diagnosis and treatment of TNBC.
• The system effectively delivers chemotherapy, enhances diagnostic imaging via MRI, and exerts therapeutic effects through hyperthermia and targeted drug delivery.
• This nanomicellar platform demonstrates potential for inhibiting TNBC metastasis and improving therapeutic outcomes.